Day: December 1, 2021

ACCUSTEM SCIENCES LIMITED (‘ACCUSTEM UK’) and ACCUSTEM SCIENCES INC (‘ACCUSTEM US’): Recommended corporate reorganisation by means of a Scheme of Arrangement under Part 26 of the Companies Act 2006

Ultragenyx Announces First Patient Dosed in Phase 1/2 Clinical Study of UX053, an mRNA Therapy for the Treatment of Glycogen Storage Disease Type III

NOVATO, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development...

Werewolf Therapeutics to Present Preclinical Data on INDUKINE™ Molecules at the 63rd American Society of Hematology (ASH) Annual Meeting

Data demonstrates the strength of Werewolf’s innovative therapeutic approach across multiple conditionally activated pipeline programsCAMBRIDGE, Mass., Dec. 01, 2021 (GLOBE...

Zogenix Announces U.S. FDA Acceptance for Priority Review of Supplemental New Drug Application for FINTEPLA® (Fenfluramine) for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)

BeyondSpring Pharmaceuticals Receives Complete Response Letter from the FDA for Plinabulin New Drug Application for Prevention of Chemotherapy-Induced Neutropenia (CIN)

NEW YORK, Dec. 01, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company...

error: Content is protected !!